Pre-emption prevails in California cases
This article was originally published in The Gray Sheet
Executive Summary
California appellate courts rule in favor of FDA pre-emption of state tort liability claims involving PMA-approved devices in two separate cases Jan. 16 and Jan. 11. The case of Blanco v. Baxter, decided in California's fourth district, involved a patient who received a PMA-approved Baxter Edwards-Duromedics model 9120 mitral bileaflet heart valve and later died from a complication. In Jessen v. Mentor, decided in the second district, a plaintiff was implanted with a Mentor testicular prosthesis that had not been filled with saline prior to its implantation. Separately, a U.S. Supreme Court review of a PMA pre-emption case (Riegel v. Medtronic) remains ongoing (1"The Gray Sheet" Jan. 7, 2008, p. 10)
You may also be interested in...
Heart valve suit
A news brief appearing in the Jan. 21, 2008, issue (1back cover) incorrectly stated that a patient death at issue in Blanco v. Baxter - a case decided by a California appeals court in favor of a heart valve device manufacturer that was sued for wrongful death - prompted a Class I recall of the device. In fact, the product recall occurred in 1988 and the patient death in question occurred in 2002
Capitol Hill Roundup: Many Med-Tech Issues Are In Play For 2008
Health care may not have been the most debated issue on Capitol Hill in 2007, but it was close, and issues impacting the medical technology sector were in abundance
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.